If you would like to ask our webinar guest speakers from WS Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund a question please submit them here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Here's my bit for other newbie investors looking to take a bite at Biotech sector: http://markets.ft.com/research/Markets/Tearsheets/Business-profile?s=SUN:LSE
I bought after order went through at open, though only a 5% weighting, which I'd say is the average of all my AIM stocks in trading account.
The Share Magazine's rec on a stop loss wasn't 3.8p, but 4.8p. Still undecided on whether to buy big or to buy a position and then top up on a fall? Its just gona have to wait until 16/17th October until I hear about US news.
Stop loss at 3.8 is 10% below the 52 week low so pretty safe really. If I can pick up below 5p I'm very happy, as these fluctuations in SP have no direct bearing on the current performance of the company taking the Interims as a guide. It is my opinion that the business is well balanced with ability to outperform 1st half by a good margin. I therefor consider the company SP to be undervalued by at least 20% and feel comfortable that the value will be recognised over the coming months.
I think a stop loss@ .38pmuch tt low IMO if this goes down to 2p it"ll bedtime bail out. I doubt if Obahma's Medicaid or Medicare programmes will make much difference either way. The greatest danger is from a competitor coming up with amore efficient or cheaper process.
This weeks Share Magazine had this stock mentioned. Shows growth, and is medium risk, and has earning power... They have a stop loss at 0.38p. I need to go away and do some research over weekend.
What a difference 3 days make? Hope you make similar %rise in PLE. GL
Sold out 100,000 this morning and put it into PLE as I think it could move faster and further short term but may come back at some time. SUN have a bright future but could take a while GLA
If Obahma gets his way we should see a rise in the sp as the Medicaid bill should encourage more operations,although there is bound to be a considerable time lag. It would be nice to know how well sales are going in the rest of the world.
might be joining the party :) http://uk.advfn.com/p.php?pid=chartscreenshotshow&u=FNHWg2B1olTim/pJa+emwFrqIF5mfHr48Pze2aeAuwM=&symbol=L%5EGDL could be a nice run north and youll get your exit target ;)
...still expensive on EV/EBIT and no cash so relying on increased borrowing to fund WC & significant spend on intangibles... ...aaoo ...I focus on cashflow statements here (and B/S) not so much the P&L
Bit worrying if our making a fortune is reliant on penguins. Lol
Leading Minimally Invasive Surgery (MIS) vet Romain Pizzi has revealed how he has used Surgical Innovations (SI) instruments to carry out keyhole surgery on penguin's that had swallowed foreign objects. The Royal Zoological Society of Scotland (RZSS) vet, a pioneer in using MIS techniques, spoke of the operations whilst presenting his work at the 8th International Penguin Conference in Bristol. He added that 'Gentoo' penguins are very inquisitive, and over the years have swallowed anything from sticks, twigs, stones, gloves, children's socks, lolly pop sticks, batteries, a broken broom handle and coins. Over the years, Romain has carried out several minimally invasive endoscopic surgical procedures in penguins; many of which he was able to use SI's instruments such as the PretzelFlex™, the world's first pretzel shaped organ retractor. The PretzelFlex™ 3mm is part of SI's 'Ultra' MIS range, which have been specially designed to allow surgeons and veterinary surgeons, like Romain, to perform operations through small 3mm holes; wounds that heal rapidly. PretzelFlex™ is inserted straight through a 3mm cannula before the innovative 'pretzel' shape is formed and locked rigidly into place. The pioneering device is renowned for its impressive strength and stability to support large organs and provides clinicians with improved access and visualisation of surgical sites. Speaking at the congress, Romain said: "Minimally invasive techniques (MIS) hold notable advantages over open surgery, including small wounds, rapid recovery, minimal post-operative pain, rapid healing, and low rates of wound complications. New cutting-edge instruments such as the 3mm PretzelFlex™ are brilliant and now allow operations to be performed that were pretty much impossible until recently, especially in difficult patients such as penguins." "These advantages also allow a more rapid return to water, important in aquatic animals such as penguins, whose natural behaviour is to spend much of their time swimming. Endoscopy also provides magnified visualisation of organs as well, as some anatomic regions are difficult to adequately visualise in open surgery. I am pleased to say the penguins in question were fine and were able to get back into the water soon after surgery." Graham Bowland, CEO of Surgical Innovations, said: "I am delighted that once again our laparoscopic instruments have helped Romain in his operative techniques on the animals at Edinburgh Zoo. Such operations help promote the zoo as a pioneering centre for wildlife and minimally invasive surgery and firmly establish Minimally Invasive Surgery as a viable proposition for animals of all sizes, including Penguins."
Thought it wuz back to 7.20.. was gonna say.. this is where I came in lol
Sun tickling your fancy mate?
A nice neat analysis, if you add in nice cash flow and a clean balacnce sheet the sp will fly back to 10-12p if the company would only state when they expected to pay a dividend..
I bought back in earlier this month, just a small investment, on the feeling that the SP had dropped back to a reasonably low level. The news regarding prospects in the USA, an expanding market place away from the surgical environment, and an economy that demands high-quality lower-cost equipment provided me with some reassurance that both the short-term and long-term future of the company are positive. If memory serves me well, then the SP reached 12p(ish) with some investors hoping for a sales-drive increase in the SP and a dividend payment, however, the dividend did not appear and dilution spoiled the party, so investors slowly sold out. Steady sales figures, concerns about costs and a press release regarding a move to new premises that could impact on production kept the SP on a downward trend for the last year. The figures at the end of 2012 were lower due to a sale being carried over into the next period. The latest figures look good, partly to this carried over amount (~£1M?). The most recent news stated that the funding for the new premises is in place (£5.05M from a regional growth fund) and that there will not be any supply issues, and that 25 NHS hospitals have signed up to use SI’s products this year. If I have to commit to bull or bear, then I will have to say that I am bull(ish).
Does modsas point about dilutions recently ring a bell? Quite apart from the acknowledged uncertainty in the maintenance of product availability due to the lack of capacity-now hopefully about to be resolved. These sorts of issues can easily put the wind up any investor.Long term Im quite relaxed. And in the end its a penny stock - and in my limited experience that's a different universe- good luck!
Can someone please enlighten me as to what caused the drop back from early 2012? Thanks
NMR_ Spin ateotd------bull or bear?
Not a lot to dislike about this company, there is so much going on in the background, I particularly appreciate the move into industrial applications with Rolls Royce, I see this as a potential game changer in the next 12 months or so. Most stocks are manipulated for short term gains, Bad news travels faster and further than good. However I anticipate good news in the coming months so continued upside.
I have bought and sold several times over the years, starting during the transition from a Haem-based company. The shares peaked at 12p(ish) and then appeared to slide back to 5p(ish), in part, due to concerns regarding the ability to guarantee supply products. The recent press release highlighted favourable figures, which was repeated in the latest Investor's Chronicle. However, I personally was most interested and encouraged by the statement that the production-capacity issues had been resolved. My question regards the general feeling of posters on this board, is Surgical Innovation going to experience a long steady period of growth, or is sentiment still suggesting a "boom and bust" spikes?
Very interesting. ............. Leeds Bradford Airport and Surgical Innovations (SI) - a designer and manufacturer of creative solutions for minimally invasive surgery (‘MIS’) - welcomed an influential Japanese investor to the region this week. The President and Chief Executive of AMCO, Akihito Koshikawa, flew to Leeds Bradford from Tokyo with British Airways to visit Surgical Innovations headquarters in Leeds. The visit highlights the importance of Leeds Bradford Airport's British Airways service to facilitate inbound investment opportunities and develop international business growth for the region. Akihiro Koshikawa spent two days at Surgical Innovations with co-founder Professor Mike McMahonand CEO Graham Bowland, where he participated in a tour of their design and manufacturing facilities. He also met key members of SI’s team, including designers, to discuss current and future product developments. Headquartered in Tokyo and with six regional offices across Japan, AMCO is a private company established in 1951 employing 180 people. The company sell a range of medical devices including SI’s pioneering range of Resposable® laparoscopic instruments, which combines reusable and single use elements, to offer high quality, cost effective solutions. Akihiro Koshikawa, President of AMCO, said: “Good connectivity with British Airways from Tokyo to Leeds makes business trips like this much easier and helps build stronger relationships between our two countries. I now look forward to welcoming the Surgical Innovations to Japan later this month to discuss further joint business activity. He added: " Surgical Innovations has transformed in size since my last visit to the Leeds city region so it was important to see the huge amounts of investment the company has made in terms of design and manufacturing and also meet the people behind the products". Impressed with the facilities and the new procedures such as Lean Manufacturing being introduced at Surgical Innovations Mr Koshikawa spoke about how a culture changes among Japanese surgeons is leading to an increased demand for Surgical Innovations products. He added: “Many key Japanese clinical opinion leaders’ are now ready to look at the economic aspect of surgical instruments and more inclined to use instruments that can save their hospital money. Surgical Innovations products are cost effective but they don’t comprise on quality, safety or performance which is the reason why there is now a higher demand for their products across Japan.” Graham Bowland, CEO of Surgical Innovations, said: “As an export focused company looking to expand their global presence, it is important that there is a strong international airport here in Leeds. We regularly have global partners visiting our head office in order to strengthen business relationships, and they are always impressed by what the Region